197 related articles for article (PubMed ID: 21562807)
1. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38).
Bzyl J; Lederle W; Rix A; Grouls C; Tardy I; Pochon S; Siepmann M; Penzkofer T; Schneider M; Kiessling F; Palmowski M
Eur Radiol; 2011 Sep; 21(9):1988-95. PubMed ID: 21562807
[TBL] [Abstract][Full Text] [Related]
2. The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55).
Bzyl J; Palmowski M; Rix A; Arns S; Hyvelin JM; Pochon S; Ehling J; Schrading S; Kiessling F; Lederle W
Eur Radiol; 2013 Feb; 23(2):468-75. PubMed ID: 22878592
[TBL] [Abstract][Full Text] [Related]
3. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
[TBL] [Abstract][Full Text] [Related]
4. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.
Tardy I; Pochon S; Theraulaz M; Emmel P; Passantino L; Tranquart F; Schneider M
Invest Radiol; 2010 Oct; 45(10):573-8. PubMed ID: 20808233
[TBL] [Abstract][Full Text] [Related]
6. Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment.
Grouls C; Hatting M; Rix A; Pochon S; Lederle W; Tardy I; Kuhl CK; Trautwein C; Kiessling F; Palmowski M
Radiology; 2013 May; 267(2):487-95. PubMed ID: 23360735
[TBL] [Abstract][Full Text] [Related]
7. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS
Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339
[TBL] [Abstract][Full Text] [Related]
8. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
Helbert A; Von Wronski M; Colevret D; Botteron C; Padilla F; Bettinger T; Tardy I; Hyvelin JM
Invest Radiol; 2020 Oct; 55(10):657-665. PubMed ID: 32229739
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound Molecular Imaging of the Breast Cancer Neovasculature using Engineered Fibronectin Scaffold Ligands: A Novel Class of Targeted Contrast Ultrasound Agent.
Abou-Elkacem L; Wilson KE; Johnson SM; Chowdhury SM; Bachawal S; Hackel BJ; Tian L; Willmann JK
Theranostics; 2016; 6(11):1740-52. PubMed ID: 27570547
[TBL] [Abstract][Full Text] [Related]
10. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model.
Lee DJ; Lyshchik A; Huamani J; Hallahan DE; Fleischer AC
J Ultrasound Med; 2008 Jun; 27(6):855-66. PubMed ID: 18499845
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).
Pysz MA; Foygel K; Rosenberg J; Gambhir SS; Schneider M; Willmann JK
Radiology; 2010 Aug; 256(2):519-27. PubMed ID: 20515975
[TBL] [Abstract][Full Text] [Related]
12. Effects of acoustic radiation force on the binding efficiency of BR55, a VEGFR2-specific ultrasound contrast agent.
Frinking PJ; Tardy I; Théraulaz M; Arditi M; Powers J; Pochon S; Tranquart F
Ultrasound Med Biol; 2012 Aug; 38(8):1460-9. PubMed ID: 22579540
[TBL] [Abstract][Full Text] [Related]
13. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo.
Willmann JK; Lutz AM; Paulmurugan R; Patel MR; Chu P; Rosenberg J; Gambhir SS
Radiology; 2008 Sep; 248(3):936-44. PubMed ID: 18710985
[TBL] [Abstract][Full Text] [Related]
14. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
[TBL] [Abstract][Full Text] [Related]
15. Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging.
Deshpande N; Ren Y; Foygel K; Rosenberg J; Willmann JK
Radiology; 2011 Mar; 258(3):804-11. PubMed ID: 21339349
[TBL] [Abstract][Full Text] [Related]
16. Quantitative ultrasound molecular imaging by modeling the binding kinetics of targeted contrast agent.
Turco S; Tardy I; Frinking P; Wijkstra H; Mischi M
Phys Med Biol; 2017 Mar; 62(6):2449-2464. PubMed ID: 28240217
[TBL] [Abstract][Full Text] [Related]
17. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
[TBL] [Abstract][Full Text] [Related]
18. Nilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response.
Zafarnia S; Bzyl-Ibach J; Spivak I; Li Y; Koletnik S; Doleschel D; Rix A; Pochon S; Tardy I; Koyadan S; van Zandvoort M; Palmowski M; Kiessling F; Lederle W
Neoplasia; 2017 Nov; 19(11):896-907. PubMed ID: 28938160
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.
Wang H; Kaneko OF; Tian L; Hristov D; Willmann JK
Invest Radiol; 2015 May; 50(5):322-9. PubMed ID: 25575176
[TBL] [Abstract][Full Text] [Related]
20. Ultra-Low-Dose Ultrasound Molecular Imaging for the Detection of Angiogenesis in a Mouse Murine Tumor Model: How Little Can We See?
Wang S; Herbst EB; Mauldin FW; Diakova GB; Klibanov AL; Hossack JA
Invest Radiol; 2016 Dec; 51(12):758-766. PubMed ID: 27654582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
